A Phase 2 interventional study of Durvalumab and Laboratory Biomarker Analysis in Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC v7, sponsored by SWOG Cancer Research Network. Completed at 1,021 sites in United States. Per ClinicalTrials.gov, last updated 2023-06-09.
Sponsored by SWOG Cancer Research Network · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This phase II trial studies how well durvalumab and tremelimumab works in treating patients with stage IV lung cancer that has come back after previous treatment. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread.
PRIMARY OBJECTIVES:
I. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 among patients treated with durvalumab (MEDI4736) plus tremelimumab.
SECONDARY OBJECTIVES:
I. To estimate the duration of response (DoR) among patients who achieve a complete response (CR) or partial response (PR) (confirmed and unconfirmed) by RECIST 1.1.
II. To estimate the duration of response (DoR) per immune-related response criteria among patients who achieve a complete response (CR) or partial response (PR) (confirmed and unconfirmed) by RECIST 1.1.
III. To evaluate overall survival (OS) among patients treated with durvalumab (MEDI4736) plus tremelimumab.
IV. To evaluate investigator-assessed progression-free survival (IA-PFS) among patients treated with durvalumab (MEDI4736) plus tremelimumab.
V. To evaluate IA-PFS assessed by immune-related response criteria (irRC-IA-PFS) among patients treated with durvalumab (MEDI4736) plus tremelimumab.
VI. To evaluate the frequency and severity of toxicities associated with durvalumab (MEDI4736) plus tremelimumab.
TERTIARY OBJECTIVES:
I. To explore the association of potential predictive markers identified in S1400A, with response and progression-free survival (PFS).
II. To explore the association of PD-L1 expression status with response and PFS.
III. To contribute to an ongoing serum and tumor bank in S1400.
OUTLINE:
Patients receive tremelimumab intravenously (IV) over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 2 years, and then at the end of year 3.
SWOG Cancer Research Network is the lead sponsor of 339 studies on the registry; 37 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Biological: Durvalumab · Other: Laboratory Biomarker Analysis · Biological: Tremelimumab
Given IV
Also known as: Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
Correlative studies
Given IV
Also known as: Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, ticilimumab
Objective Response Rate
Percentage of participants with confirmed or unconfirmed, complete or partial response to treatment with MEDI4736 (durvalumab) plus tremelimumab per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Complete Response (CR): Complete disappearance of all target and non-target lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to \< 1.0 cm. All disease must be assessed using the same technique as baseline. Partial Response (PR): Applies only to patients with at least one measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. All target measurable lesions must be assessed using the same techniques as baseline.
Time frame: From date of registration to progression or treatment discontinuation, up to 2 years and 5.5 months.
Duration of Response (DoR) Among Patients Who Achieve a Complete Response (CR) or Partial Response (PR) (Confirmed and Unconfirmed) by RECIST 1.1.
Time from date of first documentation of response (CR or PR) to date of first documentation of progression assessed by local review or symptomatic deterioration, or death from any cause among patients who achieve a response. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan will be used as the date of progression. Progression is defined as one or more of the following: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm; Unequivocal progression of non-measurable disease in the opinion of the treating physician (explanation must be provided); Appearance of any new lesion/site; Death due to disease without prior documentation of progression and without symptomatic deterioration
Time frame: From date of registration to maximum of 2 years and 5.5 months or death.
Duration of Response (DoR) Per Immune-related Response Criteria Among Patients Who Achieve a Complete Response (CR) or Partial Response (PR) (Confirmed and Unconfirmed) by RECIST 1.1
Time from date of first documentation of response (CR or PR) to date of first documentation of irRC-progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of irRC-progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan(s) determine irRC-progression, the date of irRCprogression will be the expected date of the first missing scan (as defined by the disease assessment schedule) or the date of the first scan documenting potential irRC-progression, whichever is earliest.
Time frame: From date of registration to maximum of 2 years and 5.5 months or death
Overall Survival (OS) Among Patients Treated With MEDI4736 (Durvalumab) Plus Tremelimumab
Time from date of sub-study registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
Time frame: Date of registration to maximum of 2 years and 5.5 months or death.
Investigator-assessed Progression-free Survival (IA-PFS) Among Patients Treated With MEDI4736 (Durvalumab) Plus Tremelimumab.
Time from date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) was used as the date of progression. Progression is defined as one or more of the following: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm; Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided); Appearance of any new lesion/site; Death due to disease without prior documentation of progression and without symptomatic deterioration.
Time frame: From date of registration to maximum 2 years and 5.5 months or death.
Investigator-assessed Progression-free Survival (IA-PFS) Assessed by Immune-related Response Criteria (irRC-IA-PFS) Among Patients Treated With MEDI4736 (Durvalumab) Plus Tremelimumab
Time from date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression. irRC-progression is defined by progression per RECIST 1.1 except that progression determined by appearance of new lesions or by a 20% increase in the sum of diameters must be confirmed by a second consecutive determination of progression at least 28 days from the date of initial documentation of progression.
Time frame: Date of registration to maximum of 2 years and 5.5 months or death
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
Only adverse events that are possibly, probably or definitely related to study drug are reported. CTCAE Version 4.0 was used for routine toxicity reporting and CTCAE Version 5.0 was used for reporting serious adverse events (SAEs).
Time frame: Duration of treatment and follow up until death or 2 years and 5.5 months post registration
| Milestone | Treatment (Tremelimumab, Durvalumab) |
|---|---|
| Started | 58 |
| Completed | 0 |
| Not completed | 58 |
| Withdrew: Adverse event | 8 |
| Withdrew: Disease progression | 46 |
| Withdrew: Death | 4 |
Percentage of participants with confirmed or unconfirmed, complete or partial response to treatment with MEDI4736 (durvalumab) plus tremelimumab per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Complete Response (CR): Complete disappearance of all target and non-target lesions. No new lesions. No disease related symptoms. Any lymph nodes (whether target or non-target) must have reduction in short axis to \< 1.0 cm. All disease must be assessed using the same technique as baseline. Partial Response (PR): Applies only to patients with at least one measurable lesion. Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. All target measurable lesions must be assessed using the same techniques as baseline.
| percentage of participants | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort |
|---|---|---|
| Objective Response Rate | 7 (0 to 17) | 0 (NA to NA) |
Time from date of first documentation of response (CR or PR) to date of first documentation of progression assessed by local review or symptomatic deterioration, or death from any cause among patients who achieve a response. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan will be used as the date of progression. Progression is defined as one or more of the following: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm; Unequivocal progression of non-measurable disease in the opinion of the treating physician (explanation must be provided); Appearance of any new lesion/site; Death due to disease without prior documentation of progression and without symptomatic deterioration
| months | Treatment (Tremelimumab, Durvalumab) |
|---|---|
| Duration of response for the first responding patient in the primary resistance cohort | 8.5 |
| Duration of response for the second responding patient in the primary resistance cohort | 5.9 |
Time from date of first documentation of response (CR or PR) to date of first documentation of irRC-progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of irRC-progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan(s) determine irRC-progression, the date of irRCprogression will be the expected date of the first missing scan (as defined by the disease assessment schedule) or the date of the first scan documenting potential irRC-progression, whichever is earliest.
No measurements were reported for this outcome.
Time from date of sub-study registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
| months | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort |
|---|---|---|
| Overall Survival (OS) Among Patients Treated With MEDI4736 (Durvalumab) Plus Tremelimumab | 7.7 (4.0 to 12.0) | 7.6 (5.3 to 10.2) |
Time from date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) was used as the date of progression. Progression is defined as one or more of the following: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm; Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided); Appearance of any new lesion/site; Death due to disease without prior documentation of progression and without symptomatic deterioration.
| months | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort |
|---|---|---|
| Investigator-assessed Progression-free Survival (IA-PFS) Among Patients Treated With MEDI4736 (Durvalumab) Plus Tremelimumab. | 2.0 (1.6 to 3.0) | 2.1 (1.6 to 3.2) |
Time from date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause. Patients last known to be alive without report of progression are censored at date of last disease assessment. For patients with a missing scan (or consecutive missing scans) whose subsequent scan determines progression, the expected date of the first missing scan (as defined by the disease assessment schedule) will be used as the date of progression. irRC-progression is defined by progression per RECIST 1.1 except that progression determined by appearance of new lesions or by a 20% increase in the sum of diameters must be confirmed by a second consecutive determination of progression at least 28 days from the date of initial documentation of progression.
No measurements were reported for this outcome.
Only adverse events that are possibly, probably or definitely related to study drug are reported. CTCAE Version 4.0 was used for routine toxicity reporting and CTCAE Version 5.0 was used for reporting serious adverse events (SAEs).
| Participants | MEDI4736 + Tremelimumab |
|---|---|
| Atrial fibrillation | 1 |
| Atrial flutter | 1 |
| Chills | 1 |
| Confusion | 1 |
| Creatinine increased | 1 |
| Death NOS | 1 |
| Dehydration | 3 |
| Diarrhea | 4 |
| Dyspnea | 5 |
| Encephalopathy | 1 |
| Fatigue | 1 |
| Febrile neutropenia | 1 |
| Generalized muscle weakness | 1 |
| Hyperglycemia | 1 |
| Hypoxia | 2 |
| Lung infection | 1 |
| Lymphocyte count decreased | 3 |
| Nausea | 1 |
| Neutrophil count decreased | 1 |
| Platelet count decreased | 3 |
| Pneumonitis | 2 |
| Rash maculo-papular | 1 |
| Vomiting | 1 |
| White blood cell decreased | 1 |
Collected over Duration of treatment and follow-up until death or 3 years post registration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEDI4736 + Tremelimumab | 47/58 (81%) | 36/58 (62.1%) | 58/58 (100%) |
| Event | MEDI4736 + Tremelimumab |
|---|---|
| DiarrheaGastrointestinal disorders | 9/58 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 7/58 |
| Neoplasms benign, malignant and unspecified - OtherNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/58 |
| Lung infectionInfections and infestations | 4/58 |
| VomitingGastrointestinal disorders | 3/58 |
| Death NOSGeneral disorders | 3/58 |
| Creatinine increasedInvestigations | 3/58 |
| AnorexiaMetabolism and nutrition disorders | 3/58 |
| DehydrationMetabolism and nutrition disorders | 3/58 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 3/58 |
| Event | MEDI4736 + Tremelimumab |
|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 25/58 |
| AnemiaBlood and lymphatic system disorders | 24/58 |
| FatigueGeneral disorders | 24/58 |
| HypoalbuminemiaMetabolism and nutrition disorders | 20/58 |
| HyponatremiaMetabolism and nutrition disorders | 18/58 |
| NauseaGastrointestinal disorders | 16/58 |
| AnorexiaMetabolism and nutrition disorders | 16/58 |
| Lymphocyte count decreasedInvestigations | 15/58 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/58 |
| PruritusSkin and subcutaneous tissue disorders | 14/58 |
Eligible and evaluable participants
| Age, Continuous(years) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Median | 67.6 (49.7 to 89.8) | 67.8 (46.6 to 84.0) | 67.7 (46.6 to 89.8) |
| Sex: Female, Male(Participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Female | 10 | 12 | 22 |
| Male | 18 | 18 | 36 |
| Race/Ethnicity, Customized(participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Race : White | 24 | 26 | 50 |
| Race : Black | 3 | 3 | 6 |
| Race : Native American | 1 | 0 | 1 |
| Race : Not reported | 0 | 1 | 1 |
| Hispanic ethnicity | 1 | 3 | 4 |
| Number of prior lines of therapy for stage IV disease(Participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| <2 | 9 | 12 | 21 |
| ≥2 (max 4) | 19 | 18 | 37 |
| Progression-free survival on prior anti-PD- ( L)1 therapy(months) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Median | 3.0 (1.4 to 5.5) | 10.0 (5.6 to 30.4) | 5.5 (1.4 to 30.4) |
| Best response to prior anti-PD- ( L)1 therapy(Participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Complete response | 0 | 3 | 3 |
| Partial response | 2 | 7 | 9 |
| Stable disease | 11 | 20 | 31 |
| Progressive disease | 15 | 0 | 15 |
| Performance status(Participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| 0 | 7 | 10 | 17 |
| 1 | 21 | 20 | 41 |
| Smoking status(Participants) | Primary PD-(L)1 Resistance Cohort | Acquired PD-(L)1 Resistance Cohort | Total |
|---|---|---|---|
| Current smoker | 10 | 10 | 20 |
| Former smoker | 17 | 19 | 36 |
| Never smoker | 1 | 1 | 2 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 1,021 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in May 2020, 29 months.
Results were first posted in Jan 2022, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tremelimumab
SWOG Cancer Research Network →